Be part of the knowledge.™

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.

3148

LikeLikedUnlike

586-600 of 927

The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
- William J. Gradishar, MD
  Peer
1.50 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
- Sara Lonardi, MD
  Peer
1.25 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
- Sara Lonardi, MD
  Peer
1.25 program credits
advertisement
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
- Sara Lonardi, MD
  Peer
1.25 program credits
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
- Alan Venook, MD
  Peer
1.25 program credits
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
MinuteCE®
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
- Aparna R. Parikh, MD
  Peer
1.25 program credits
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
- Aparna R. Parikh, MD
  Peer
1.25 program credits
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
- Aparna R. Parikh, MD
  Peer
1.25 program credits
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
- Alan Venook, MD
  Peer
1.25 program credits
advertisement
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
- Alan Venook, MD
  Peer
1.25 program credits
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
- Sara Lonardi, MD
  Peer
- Aparna R. Parikh, MD
  Peer
- Alan Venook, MD
  Peer
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
- Ignacio Duran, MD
  Peer
- Wenxin Xu, MD
  Peer
- Sandy Srinivas, MD
  Peer
1.25 credits 10 episodes

Program Chapters

Segment Chapters

Playlist:

Recommended